Why did IDYA's Q4 earnings surprise analysts?

IDEAYA Biosciences' Q4 earnings exceeded analysts' expectations due to a combination of factors:

1. **Revenue Surprise**: The company's total revenue for Q4 was $7 million, with a revenue surprise of $2.46 million. This positive surprise indicates that the company's actual performance exceeded analysts' estimates.

|code|Ticker|Name|Date|Revenue Surprise|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|IDYA|IDYA.O|IDEAYA Biosciences|2024 Q1|-4450000||185|
|IDYA|IDYA.O|IDEAYA Biosciences|2024 Q2|-4860000||185|
|IDYA|IDYA.O|IDEAYA Biosciences|2024 Q3|-3750000||185|
|IDYA|IDYA.O|IDEAYA Biosciences|2024 Q4|2460000|7000000|185|

2. **Business Performance**: IDEAYA Biosciences has been actively involved in the precision medicine oncology sector, focusing on targeted therapies. The company's strategic focus and operational efficiency likely contributed to the positive earnings surprise.

In conclusion, IDEAYA Biosciences' Q4 earnings exceeded analysts' expectations due to a combination of strong revenue performance and effective business strategies.